PEOPLE - Changes at Andaris (UK):
This article was originally published in Clinica
Executive Summary
Andaris, a UK developer of in vivo imaging and therapeutic products, has appointed Dr Stuart Collinson of Glaxo Wellcome CEO. David Heath, Andaris' lead founder, has retired as chairman but remains a non-executive director and consultant to the UK company. Gordon Hall, previously managing director of Shield Diagnostics, joins as non-executive chairman.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.